Every tumor is different. Every treatment should be too.
We use AI to find the neoantigens that matter for one person, then design a drug built around them.
Cancer cells carry mutations that healthy cells don't. Some of those mutations create neoantigens, markers the immune system can learn to recognize.
Each patient's tumor produces its own set, which is why a treatment built for one person's cancer rarely works for another's.
From a tumor sample to a personalized drug
Our platform turns a patient's own tumor data into a treatment candidate in five steps.
Sequence
We sequence a patient's tumor and healthy tissue to map the mutations that are unique to the cancer.
Find
Our AI models scan those mutations and predict which ones produce neoantigens.
Prioritize
Not every neoantigen is a good target. We rank them by how likely the patient's own immune system is to see and respond to them.
Design
We design a personalized drug aimed at the top-ranked neoantigens, with AI guiding the design for that one patient.
Validate
Every candidate is tested in the lab and reviewed by scientists and clinicians before it moves toward treatment. Each result feeds back into our models.
What is a neoantigen?
Why the immune system can tell a tumor cell from a healthy one.
A neoantigen is a protein fragment found on cancer cells but not on healthy ones, created by mutations in the tumor's DNA.
Because healthy cells don't carry it, a neoantigen gives the immune system a precise target.
A single tumor can carry hundreds to thousands of mutations, and only a few become useful targets. Checking each one by hand is slow. Machine learning lets us evaluate them quickly and estimate how each is likely to look to a patient's immune system.
Personal by design
No two patients receive the same drug. Each one is built from that patient's own tumor.
AI where it helps
Models find and rank targets. Scientists and clinicians make the decisions.
Open about evidence
We share what we have shown and what is still unproven.
The immune cells behind the response
Neoantigens only matter if the immune system can act on them.
A few cell types do most of the work of finding and destroying tumor cells.
Our models weigh how a candidate neoantigen is likely to engage these cells, not just whether it looks distinctive on paper.
CD8+ Killer T cell
CD3+, CD8+Finds tumor cells displaying a neoantigen it recognizes and destroys them directly.
Natural killer cell
CD16+, CD56+Attacks abnormal cells that try to hide by lowering the markers T cells look for.
CD4+ helper T cell
CD3+, CD4+Coordinates the response, activating killer T cells, B cells, and other immune cells.
Dendritic cell
CD11c+, MHC class II+Captures tumor antigens and presents them to T cells, starting the response.
Macrophage
CD14+, CD68+Engulfs tumor cells and signals for backup, though some tumors try to turn it to their advantage.
B cell
CD19+, CD20+Produces antibodies against tumor antigens and helps coordinate the wider response.
Clinical trials
What it takes before a personalized drug reaches a patient.
Our first clinical programs are in preparation.
Personalized therapies are investigational, and none has been approved for general use. If you are a patient, caregiver, or physician, tell us you're interested and we'll share updates as enrollment plans are confirmed.
T-Cell Pharma does not give medical advice. Talk to your oncologist about the options available to you today.
Ask about trialsWork with us
Finding a cure takes many hands. We collaborate across research, care, and industry.
Researchers and institutions
Collaborate on neoantigen discovery, validation, and shared datasets.
Start a collaborationClinicians and hospitals
Help advance new treatments through clinical research.
Talk to our teamBiopharma
Partner on manufacturing, development, or new cancer types.
Discuss a partnershipInvestors
Accredited investors can become part of an innovative pharmaceutical company.
Invest in us
Questions, answered
The questions we hear most about the science and what to expect.
What is personalized cancer treatment?
It is a treatment designed around the specific mutations in one patient's tumor, rather than one drug for everyone with the same type of cancer.
Does AI replace doctors?
No. Our models generate and rank candidates. Oncologists and scientists review them and make the clinical decisions.
Can I receive treatment now?
Not yet outside of clinical research. Our therapies are investigational. Contact us about trials, and talk to your oncologist about options available today.
Will this work for every cancer?
We don't know yet. Neoantigen approaches depend on the tumor and on the patient's immune system, which is why we test each candidate and study the results carefully.
Let's find a cure together.
Questions about our science, trials, or partnerships? We read every message.
hello@tcellpharma.com